Modulation of the malignant phenotype with the urokinase-type plasminogen activator and the type I plasminogen activator inhibitor
- PMID: 2129155
- DOI: 10.1016/0922-3371(90)90040-4
Modulation of the malignant phenotype with the urokinase-type plasminogen activator and the type I plasminogen activator inhibitor
Abstract
Gene transfer techniques were utilized to evaluate the role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in enhancing or preventing the expression of the invasive malignant phenotype, respectively. Mouse L-cell transfectants expressing human uPA or human PAI-1 as well as mouse B16 transfectants expressing mouse uPA or human PAI-1 were generated. These transfectants were tested using a variety of experimental methods including smooth muscle cell matrix solubilization in vitro, lung colony formation in vivo and co-cultures of antagonist-expressing cells in vitro. Results from these studies provide direct evidence for an enhancing role of uPA in malignant invasion and experimental metastasis and for a modulatory role of PAI-1 in tumor cell-mediated breakdown of extracellular matrices.
Similar articles
-
Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion.J Cell Biol. 1989 Aug;109(2):915-25. doi: 10.1083/jcb.109.2.915. J Cell Biol. 1989. PMID: 2503527 Free PMC article.
-
Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.Cancer Res. 1990 Aug 1;50(15):4676-84. Cancer Res. 1990. PMID: 2114945
-
Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.Blood. 1996 Jun 1;87(11):4718-22. Blood. 1996. PMID: 8639841
-
The urokinase plasminogen activator system in breast cancer invasion and metastasis.Biomed Pharmacother. 2013 Mar;67(2):179-82. doi: 10.1016/j.biopha.2012.10.003. Epub 2012 Nov 15. Biomed Pharmacother. 2013. PMID: 23201006 Review.
-
Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?Eur J Surg Oncol. 2017 Feb;43(2):252-257. doi: 10.1016/j.ejso.2016.06.002. Epub 2016 Jun 20. Eur J Surg Oncol. 2017. PMID: 27345498 Review.
Cited by
-
Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.Cell Mol Life Sci. 2010 Dec;67(23):3947-60. doi: 10.1007/s00018-010-0469-5. Epub 2010 Aug 5. Cell Mol Life Sci. 2010. PMID: 20686912 Free PMC article. Review.
-
Utilization of transgenic mice in the study of matrix degrading proteinases and their inhibitors.Cancer Metastasis Rev. 1995 Jun;14(2):97-111. doi: 10.1007/BF00665794. Cancer Metastasis Rev. 1995. PMID: 7554034 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous